INSTITUTO DE INVESTIGACIÓN BIOMÉDICA DE SALAMANCA
Instituto
Fred Hutchinson Cancer Research Center
Seattle, Estados UnidosPublicaciones en colaboración con investigadores/as de Fred Hutchinson Cancer Research Center (37)
2023
-
A pleiotropic variant in DNAJB4 is associated with multiple myeloma risk
International Journal of Cancer, Vol. 152, Núm. 2, pp. 239-248
-
Integrating biological HLA-DPB1 mismatch models to predict survival after unrelated hematopoietic cell transplantation
Haematologica
-
Polymorphisms within Autophagy-Related Genes as Susceptibility Biomarkers for Multiple Myeloma: A Meta-Analysis of Three Large Cohorts and Functional Characterization
International Journal of Molecular Sciences, Vol. 24, Núm. 10
-
Profiling the immune landscape in mucinous ovarian carcinoma
Gynecologic Oncology, Vol. 168, pp. 23-31
-
Targeting Hedgehog Signaling with Glasdegib in Patients with Refractory Sclerotic Chronic GVHD: A Report of Two Phase I/II Trials
Clinical Cancer Research, Vol. 29, Núm. 20, pp. 4057-4067
2022
-
Comparison of outcomes for HLA-matched sibling and haplo-identical donors in Myelodysplastic syndromes: report from the chronic malignancies working party of EBMT
Blood Cancer Journal, Vol. 12, Núm. 9
-
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
Blood, Vol. 140, Núm. 11, pp. 1200-1228
2021
-
A multilayered post-GWAS assessment on genetic susceptibility to pancreatic cancer
Genome Medicine, Vol. 13, Núm. 1
2020
-
Avadomide monotherapy in relapsed/refractory DLBCL: safety, efficacy, and a predictive gene classifier
Blood, Vol. 135, Núm. 13, pp. 996-1007
-
Prognostic gene expression signature for high-grade serous ovarian cancer
Annals of Oncology, Vol. 31, Núm. 9, pp. 1240-1250
2019
-
Guidelines for the use of flow cytometry and cell sorting in immunological studies (second edition)
European Journal of Immunology, Vol. 49, Núm. 10, pp. 1457-1973
2018
-
An update on minding the gap in cancer
Biochimica et Biophysica Acta - Biomembranes, Vol. 1860, Núm. 1, pp. 237-243
-
Ibrutinib as treatment for patients with relapsed/refractory follicular lymphoma: Results from the open-label, multicenter, phase II DAWN study
Journal of Clinical Oncology, Vol. 36, Núm. 23, pp. 2405-2412
-
Response and progression-free survival according to planned treatment duration in patients with relapsed multiple myeloma treated with carfilzomib, lenalidomide, and dexamethasone (KRd) versus lenalidomide and dexamethasone (Rd) in the phase III ASPIRE study
Journal of Hematology and Oncology, Vol. 11, Núm. 1
2017
-
FDG-PET is prognostic and predictive for progression-free survival in relapsed follicular lymphoma: exploratory analysis of the GAUSS study
Leukemia and Lymphoma, Vol. 58, Núm. 2, pp. 372-381
2016
-
Carfilzomib significantly improves the progression-free survival of high-risk patients in multiple myeloma
Blood, Vol. 128, Núm. 9, pp. 1174-1180
-
International Myeloma Working Group Recommendations for the Diagnosis and Management of Myeloma-Related Renal Impairment
Journal of Clinical Oncology, Vol. 34, Núm. 13, pp. 1544-1557
2015
-
American Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials Network, and International Myeloma Working Group Consensus Conference on Salvage Hematopoietic Cell Transplantation in Patients with Relapsed Multiple Myeloma
Biology of Blood and Marrow Transplantation, Vol. 21, Núm. 12, pp. 2039-2051
-
Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma
New England Journal of Medicine, Vol. 372, Núm. 2, pp. 142-152
-
Identification of six new susceptibility loci for invasive epithelial ovarian cancer
Nature Genetics, Vol. 47, Núm. 2, pp. 164-171